3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Hepatocellular
35
Carcinoma, Non-Small-Cell Lung
32
Colorectal Neoplasms
19
Esophageal Squamous Cell Carcinoma
18
Stomach Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
16
Rectal Neoplasms
11
Cholangiocarcinoma
11
Head and Neck Neoplasms
10
Small Cell Lung Carcinoma
9
Lung Neoplasms
9
Esophageal Neoplasms
9
Triple Negative Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Nasopharyngeal Carcinoma
7
Urinary Bladder Neoplasms
6
Recurrence
6
Pancreatic Neoplasms
6
Neoplasms
6
Colonic Neoplasms
6
Melanoma
5
Hodgkin Disease
5
Biliary Tract Neoplasms
4
Adenocarcinoma of Lung
4
Sarcoma
3
Non-Muscle Invasive Bladder Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Locally Advanced Rectal Cancer
3
Liver Neoplasms
3
Interventions
Mitomycin
3
Hyperthermic Intraperitoneal Chemotherapy
3
Surveys and Questionnaires
2
Fluorouracil
2
Capecitabine
2
tislelizumab
1
molgramostim
1
irinotecan sucrosofate
1
Tacrolimus
1
Standard of Care
1
Sirolimus
1
Referral and Consultation
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Pharmacogenomic Testing
1
Oxaliplatin
1
Observation
1
Methods
1
Leucovorin
1
Lansoprazole
1
Ifosfamide
1
Gemcitabine
1
Early Intervention, Educational
1
Doxorubicin
1
Cytoreduction Surgical Procedures
1
Clarithromycin
1
Cisplatin
1
Carboplatin
1
Bromelains
1
Behavior Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pseudomyxoma Peritonei
×
tislelizumab
×
Clear all
NCT07341360
2026-01-14
Pseudovax
Oslo University Hospital
Phase EARLY_PHASE1
Recruiting
10 enrolled